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Available online 17 November 2015Introduction:While teriparatide is the only skeletal anabolic agent approved in the United States, treatment fail-
ure is a major concern which complicates its clinical utility. We sought to identify factors that predict response
failure in patients with low bone mass.
Method: We performed a retrospective study of adults with osteopenia or osteoporosis (T-scores b−1.0 and
−2.5 SD belownormal, respectively, at the total hip or lumbar spine) treatedwith teriparatide at theMayo Clinic
(Rochester, Minnesota) between November 2002–December 2012. Trained study investigators blinded to pa-
tient outcomes collected electronic medical record data. Potential response failure predictors were identiﬁed
using univariate analysis. Multivariable logistic regressionmodelingwas used to identify independent predictors
of treatment failure based on either osteoporotic fragility fracture or BMD response.
Results: During the 10-year period, 494 patients received teriparatide treatment and met eligibility criteria.
Thirty-ﬁve patients had osteoporotic fractures, while 172 did not achieve a ≥ 3% BMD increase. Among predictors
as deﬁned by BMD change, both prior bisphosphonate treatment [odds ratio (95% conﬁdence interval), 1.50
(1.01–2.24)] and vitamin D therapy [1.50 (1.01–2.22)] were signiﬁcantly (P b 0.05) associated with teriparatide
treatment failure. By contrast, no predictors were associated with treatment failure when fracture was the end-
point.
Conclusion: These data suggest that prior bisphosphonate or vitamin D exposure may predict response failure to
teriparatide therapy. Although theseﬁndingsmay, in part, reﬂect increased severity or longer duration of disease,
this knowledge should help guide clinicians and patients when therapy choices are made.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Osteoporosis affectsmore than 20million Americans and is associat-
ed with approximately 1.5 million fractures annually (Finkelstein et al.,
2003). Thus, osteoporosis represents a major health problem that will
onlyworsen as the population ages. The osteoporotic skeleton is charac-
terized by diminished bonemineral density (BMD), reduced bone qual-
ity, and increased fragility, all of which increase susceptibility to
fractures (Anon., 1993).
Teriparatide [recombinant human parathyroid hormone (PTH)] is a
recombinant molecule composed of the amino-terminal 34 amino
acids of human PTH (Body et al., 2002). FDA-approved in November
2002, teriparatide is the only currently available skeletal anabolicharmacology and Experimental
MN 55905, United States.
.
. This is an open access article underagent in the United States, and is most frequently reserved for patients
with severe osteoporosis or in whom other treatment modalities have
failed (Ragucci & Shrader, 2011; Andrews et al., 2012). Daily subcutane-
ous injection of teriparatide both stimulates osteoblast generation and
limits osteoblast elimination by apoptosis (Body et al., 2002), ultimately
resulting in new bone formation with increases in both bone mass and
strength (Yu et al., 2011). A randomized controlled trial (RCT) conduct-
ed by Neer et al. (2001) in 2001 reported that teriparatide signiﬁcantly
increased BMD and reduced both vertebral and non-vertebral fractures
when administered (once daily) subcutaneously at doses of either 20 or
40 micrograms (μg).
A potential drawback associated with teriparatide use is response
failure. Gallagher et al. (2006) reported this problem in a review of
three RCTs that included postmenopausal women treated with
teriparatide, in comparison to either placebo or treatment with the bis-
phosphonate, alendronate. Interestingly, when administered subcuta-
neously at a daily dose of either 20 or 40 μg, the response rate tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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from baseline of 3%, ranged from87 to 94% (Gallagher et al., 2006). Nev-
ertheless, the authors were unable to detect any differences in baseline
characteristics between patients who responded versus those who did
not. In a more recent study, Heaney & Watson (2011) reported that
the response rate to teriparatide may be more variable and somewhat
lower, with positive BMD response rates of 44.8% and 82.5% at the lum-
bar spine and total hip, respectively.
Considering that teriparatide treatment is associatedwith signiﬁcant
cost and treatment burden that includes daily injections, it is of upmost
importance to identify predictors of treatment failure. Therefore, we
aimed to establish the impact of an array of baseline characteristics
and osteoporosis-related exposures on the response to teriparatide
treatment in patients with low BMD, and to identify factors that signif-
icantly predict treatment failure.
2. Material and methods
2.1. Study participants and setting
This study was a retrospective analysis carried out using the unique
electronic medical record system at the Mayo Clinic, a tertiary care
teaching institution located in Rochester, Minnesota. The study protocol
was approved by the Mayo Clinic Institutional Review Board and all pa-
tients provided authorization for review of their medical records for re-
search in accordance with Minnesota privacy law (St Sauver et al.,
2012). To be eligible for study inclusion, patients were required to
have received teriparatide (for at least 12 months) at Mayo Clinic be-
tween 1 November 2002 and 31 December 2012. We included patients
N18 years old who were diagnosed with low bone mass (osteopenia or
osteoporosis with T-scores less than 1.0 and 2.5 SD below normal re-
spectively, at either the total hip or lumbar spine). Medical records
with missing outcome data were excluded from analysis. Patients
were not otherwise excluded based on speciﬁc baseline medical condi-
tions or medications. Outcomes evaluated were the occurrence of oste-
oporotic fracture and BMD treatment failure (deﬁned as a less than 3%
increase from baseline at either the total hip or spine).
2.2. Data source
All data were retrieved from the Mayo Clinic Life Sciences System
(MCLSS), an exhaustive clinical data warehouse which stores patient
demographics, diagnoses, clinical notes, and hospital, laboratory, ﬂow
sheet, and pathology data gathered from various clinical and hospital
source systems within the institution (Alsara et al., 2011). To conduct
the search in MCLSS, we used the query-building tool provided by
MCLSS, Data Discovery and Query Builder (DDQB), which allows a thor-
ough interrogation of MCLSS for the intended data (Alsara et al., 2011).
To ensure the reliability of this tool, wemanually retrieved fracture data
from medical records of 20 randomly selected patients. Inter-rater
agreement (k) between the tool and manual extraction was excellent
(k= 0.95).
2.3. Deﬁnitions of treatment failure
Clinical response failure was deﬁned as sustaining one ormore oste-
oporotic fractures (i.e., hip, spine, distal forearm, proximal humerus)
after the patient has been treatedwith teriparatide for at least 6months.
Osteoporotic fractures, also known as fragility or minimal-trauma frac-
tures,were deﬁned by convention as occurring from low-energy trauma
such as a fall from a standing height or less, and due to no more than
moderate trauma (e.g., motor vehicle accidents) (Rebolledo et al.,
2011). Radiographic response failure was deﬁned as b3% increase in
BMD from baseline at the spine, total hip or both when measured at
least 12 months following teriparatide initiation (Gallagher et al.,
2006). BMD measurements were obtained at time of teriparatideinitiation. For study inclusion, subjects must have had a repeat BMD de-
termination performed 12–24 months following treatment initiation.
To adjust for this variation in follow-up length from time of treatment
initiation, we calculated the average between-measurement time (re-
ferred to as follow-up duration) and included this variable in the regres-
sion model.
2.4. Ascertainment of study variables
Outcome variables were collected by study investigators who re-
trieved information about fracture occurrence as well as baseline and
follow-up BMD measurements from the electronic medical record of
the Mayo Clinic. BMDwas assessed by dual-energy X-ray absorptiome-
try (DXA) at the total lumbar spine, total hip and femoral neck using a
Lunar Prodigy scanner (General Electric Healthcare, Waukesha, WI), as
described previously (Dy et al., 2012). To reduce measurement errors,
standard practice at Mayo Clinic is to report the average of 2 scans per-
formed during each assessment. In addition, the average least signiﬁ-
cant change (LSC) in BMD for all technicians is included in order to
avoid the need for patients to have scans performed on the same ma-
chine by the same technician each time an assessment is performed.
The LSC is deﬁned as the smallest amount of change between two
BMD measurements over time that must be exceeded before a change
can be considered the result of a true difference in a patient's BMD
and not due to either DXA or patient factors with 95% conﬁdence
(Shepherd & Lu, 2007).
Predictor variables were identiﬁed a priori, and were collected from
the electronic medical records using DDQB. Based on opinions received
from a panel of content experts, in addition to a comprehensive litera-
ture search (i.e. previous studies, meta-analyses and review articles
written by experts in the bone and osteoporosis ﬁelds), we were able
to identify several variables that could be potential predictors of re-
sponse failure. These factors included: 1) demographics: age and sex;
2) anthropometric measurements: height, weight and body mass
index (BMI); 3) habitual exposures: alcohol intake and cigarette
smoking; 4) co-morbidities: hypertension, diabetes, cancer, chronic
renal disease, chronic liver disease; 5) baselinemedications and supple-
ments (i.e. bisphosphonates, corticosteroids, calcium, phosphate, pro-
ton pump inhibitors, vitamin D); and 5) biochemical parameters (i.e.
bone alkaline phosphatase, C-terminal telopeptide of type I collagen
(CTX), 25-hydroxyvitamin D, parathyroid hormone) at baseline and
after treatment completion.
2.5. Statistical analysis
Data for the predictor variables are presented asmeans and standard
deviations (SD) for variableswith normal distribution, andmedians and
interquartile ranges (IQR) for those with skewed distributions, as ap-
propriate. Categorical variables are presented as frequencies and per-
centages. Unpaired Student's t-tests were used to compare continuous
variables with normal distribution, and the Mann–Whitney U test oth-
erwise. For comparison of categorical variables, chi-square tests were
used.
Candidate predictors of responsewere identiﬁed usingunivariate lo-
gistic regression. Predictors that achieved a level of signiﬁcance equal to
a P-value of b0.05 were selected for inclusion in themultivariate model
to predict treatment failure (at least one fracture versus no fractures; or
less than a 3% increase in total hip and or spine BMD from baseline ver-
sus 3% or more). To determine the independent impact of each variable
on the response to teriparatide treatment, multivariable logistic regres-
sion models were created. We included risk factors identiﬁed from uni-
variatemodels as covariates and either fracture or BMD response failure
as dependent variables. For all analyses, a P-value b 0.05was considered
statistically signiﬁcant. Analyses were performed using STATA, version
12.1 (StataCorp LP, College Station, TX, USA).
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3.1. Participants
We included a total of 494 patients who received teriparatide in
Mayo Clinic and met the eligibility criteria for the study. Baseline char-
acteristics of the participants, according to fracture and BMD response,
are presented in Table 1. All groups were similar in age, sex, race and
BMI. Further, the fracture and non-fracture groups were similar at base-
line except for the tendency for a higher prevalence of diabetes and hy-
pertension, and prior bisphosphonate treatment in the fracture group.
In addition, when compared to those who achieved the a priori chosen
BMD response, the group that did not achieve this response contained
more current smokers and included a greater proportion of patients
who had previously been treated with bisphosphonate therapy.
Althoughwewere unable tomeasure adherencewith the prescribed
treatment directly, high compliance in this population is assumed given
the rigorous methods followed by the Mayo Clinic specialty pharmacy
in assuring timely prescription reﬁlls andmedication delivery, a process
which includes monthly phone call interaction with each patient prior
to medication issuance. In addition, we excluded all patients who did
not have both pre- and post-treatment BMD determinations as deﬁned
in the methods section.Table 1
Baseline characteristics by BMD response and fracture group.
Fracture No fracture
N (%) 35 (7.1) 459 (92.9)
Sex
Male 5 (14.3) 87 (18.9)
Female 30 (85.7) 372 (81.1)
Age 62.4 (12.4) 66.2 (12.6)
Race
Caucasian 35 (100) 439 (95.6)
African American 0 (0) 3 (0.7)
Asian 0 (0) 6 (1.3)
Other 0 (0) 11 (2.4)
Follow up (months) a 21 (17, 25) 14 (12, 22)
BMI (kg/m2) 25.2 (5.9) 25.0 (5.1)
Weight (Kg) 62.7 (21.9) 66.0 (16.4)
Smoking status
Current 3 (8.6) 20 (4.3)
Past 6 (17.1) 118 (25.7)
Never 19 (54.3) 190 (41.4)
Unknown 7 (20) 131 (28.5)
Comorbid conditions
Asthma 4 (11.4) 25 (54.5)
COPD 3 (8.6) 18 (3.9)
CAD 2 (5.7) 30 (6.5)
Diabetes 6 (17.1) 33 (7.2)
Hypertension 13 (37.1) 100 (21.8)
Liver disease 0 (0) 2 (0.4)
Malignancy 5 (14.3) 67 (14.6)
Renal disease 2 (5.7) 11 (2.4)
Baseline medication use
Bisphosphonatesb 18 (51.4) 158 (34.4)
Corticosteroids 12 (34.3) 95 (20.7)
Calcium 13 (37.1) 109 (23.7)
Phosphate 0 (0) 3 (6.5)
PPIs 11 (31.4) 85 (18.5)
Vitamin D 23 (65.7) 227 (49.4)
Baseline lab valuesa,c
BAP (μg/L) 18 (10.45, 24) 14 (10.5, 22)
CTX (pg/mL) 167 (139, 1188) 668 (396, 899)
Vitamin D (ng/mL) 33 (27, 51) 35 (29.5, 47)
PTH (pg/mL) 37 (23, 49) 27 (22, 37.5)
Data are presented as mean (SD) or number (percentage), unless speciﬁed otherwise.
a Data are presented as median (Q1, Q3).
b The types of bisphosphonate used by patients in this study included: alendronate, etidron
c Reference ranges are as follows: BAP: adult male b 20 μg/L, adult premenopausal female b
menopausal female 25–573 pg/mL, adult postmenopausal female 104–1008 pg/mL; Vitamin D3.2. Predictors of treatment failure based on fracture incidence
In univariate analyses, multiple factors were signiﬁcantlymore com-
mon in the non-response group when deﬁned by fracture incidence.
These included age, BMI, sex, baseline comorbidities: hypertension
and malignancy, and baseline medications: bisphosphonate, calcium,
corticosteroid, proton pump inhibitors (PPIs) and vitamin D. In compar-
ison, multivariable modeling to predict non-response as deﬁned by the
occurrence of at least one osteoporotic fracture did not identify any of
these as a signiﬁcant predictor. Table 2 shows the multivariate-
adjusted analyses based on fracture incidence.
3.3. Predictors of treatment failure based on BMD change
Univariate analyses yielded multiple variables which were signiﬁ-
cantly more common in the group that failed to respond by BMD differ-
ence from baseline, including age, sex, baseline comorbidities:
hypertension and malignancy, and baseline medications: bisphospho-
nate, calcium, corticosteroid, PPIs and vitamin D. When adjustment for
these variables using multivariate logistic regression models was per-
formed, however, only two signiﬁcant baseline predictors of treatment
failure were identiﬁed: bisphosphonate therapy (OR = 1.50; 95% CI:
1.01–2.24; P = 0.045) and vitamin D treatment (OR = 1.50; 95% CI:P BMD failure BMD response P
… 172 (34.8) 322 (65.2) …
0.494 0.323
28 (16.3) 64 (19.8)
144 (83.7) 258 (80.2)
0.890 65.7 (12.2) 66.0 (12.8) 0.862
0.662 0.586
163 (94.8) 311 (96.6)
1 (0.6) 2 (0.6)
2 (1.2) 4 (1.2)
6 (3.4) 5 (1.6)
0.001 14 (12, 23) 15 (13, 22) 0.707
0.850 24.8 (5.2) 25.1 (5.1) 0.620
0.285 64.5 (17.5) 66.4 (16.5) 0.247
0.240 0.036
13 (7.5) 10 (3.1)
36 (20.9) 88 (27.3)
69 (40.1) 140 (43.5)
54 (31.4) 84 (26.0)
0.147 11 (6.4) 18 (5.6) 0.716
0.189 7 (4.1) 14 (4.3) 0.884
0.849 10 (5.8) 22 (6.8) 0.661
0.035 11 (6.4) 28 (8.7) 0.366
0.037 41 (23.8) 72 (22.4) 0.710
1.000 0 (0) 2 (0.6) 1.000
0.960 24 (13.9) 48 (14.9) 0.775
0.237 5 (2.9) 8 (2.5) 0.780
0.043 74 (43.0) 102 (31.7) 0.012
0.060 41 (23.8) 66 (20.5) 0.391
0.076 47 (27.3) 125 (38.8) 0.322
1.000 0 (0) 3 (0.9) 1.000
0.063 32 (18.6) 64 (19.9) 0.734
0.064 100 (58.1) 150 (46.6) 0.014
0.725 12 (10, 22) 16 (11, 21.7) 0.542
0.282 515 (352, 1235) 668 (288, 811) 0.650
0.694 36 (29.5, 49.5) 35 (28, 45) 0.638
0.476 26 (19.5, 37) 30 (23, 41) 0.409
ate, ibandronate, risedronate, zoledronic acid.
14 μg/L, postmenopausal female b 22 μg/L; CTX: adult male 35–836 pg/mL, adult pre-
20–50 ng/mL; PTH 15–65 pg/mL.
Table 2
Multivariate-adjusted analyses based on fracture incidence.
Fracture
(n = 35)
No fracture
(n = 459)
OR
(95% CI)
P value
Baseline demographics
Age, mean (SD) 62.4 (12.4) 66.2 (12.6) 0.98 (0.94–1.01) 0.109
BMI, mean (SD) 25.2 (5.9) 25.0 (5.1) 1.01 (0.94–1.09) 0.737
Gender, male/female (%) 5/30 (14.3/85.7) 87/372 (18.9/81.1) 0.76 (0.26–2.24) 0.621
Baseline co-morbidities
Hypertension, n (%) 13 (37.1) 100 (21.8) 2.05 (0.91–4.63) 0.085
Malignancy, n (%) 5 (14.3) 67 (14.6) 1.05 (0.37–2.97) 0.931
Baseline medications
Bisphosphonate, n (%) 18 (51.4) 158 (34.4) 1.25 (0.57–2.76) 0.580
Calcium, n (%) 13 (37.1) 109 (23.7) 1.73 (0.79–3.82) 0.171
Corticosteroids, n (%) 12 (34.3) 95 (20.7) 1.33 (0.58–3.02) 0.502
PPIs, n (%) 11 (31.4) 85 (18.5) 1.67 (0.73–3.83) 0.229
Vitamin D, n (%) 23 (65.7) 227 (49.4) 1.53 (0.68–3.43) 0.307
Abbreviations: SD: standard deviation; OR: odds ratio; BMI: body mass index; PPIs: proton pump inhibitors.
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yses based on BMD failure.
To compare the effect of different types of bisphosphonate on re-
sponse failure, we measured the OR of non-response for the group
that received alendronate or zoledronic acid compared to the group
that received other types of bisphosphonate. No statistically signiﬁcant
difference in response failure was detected between the 2 groups (OR
0.70; 95% CI: 0.26–1.90; P = 0.49).4. Discussion
We conducted a retrospective cohort study to identify possible pre-
dictors of treatment failure with teriparatide. Although approved as the
only skeletal anabolic agent in the United States, treatment with
teriparatide is associated with signiﬁcant cost, as well as a signiﬁcant
burden on patients that includes daily injections.We found that after in-
clusion of several important potential factors that may predict response
failure to teriparatide, only prior bisphosphonate treatment and vitamin
D therapy were signiﬁcant predictors.
One possible explanation for these ﬁndings may be that patients
who have received such prior treatment havemore severe osteoporosis
or disease of longer duration. An alternative (andnotmutually exclusive
explanation) is that prior bisphosphonate therapy has led to suppres-
sion of bone turnover, ultimately leading to an impaired response to
teriparatide, as teriparatide action requires both increased osteoblast
and osteoclast activity — with osteoblast (bone building) activity
predominating.Table 3
Multivariate-adjusted analyses based on BMD failure:
BMD failure
(n = 172)
B
(
Baseline demographics
Age, mean (SD) 65.7 (12.2)
Gender, male/female (%) 28/144 (16.3/83.7) 6
Baseline co-morbidities
Hypertension, n (%) 41 (23.8)
Malignancy, n (%) 24 (13.9)
Baseline medications
Bisphosphonate, n (%) 74 (43.0)
Calcium, n (%) 47 (27.3)
Corticosteroids, n (%) 41 (23.8)
PPIs, n (%) 32 (18.6)
Vitamin D, n (%) 100 (58.1)
Abbreviations: BMD: bone mineral density; SD: standard deviation; OR: odds ratio; PPIs: proto
a Independent signiﬁcant predictors.With regard to the demonstrated effect of vitamin D supplementa-
tion, a plausible explanation is that patients receiving vitamin D supple-
mentation may be at increased risk of underlying osteomalacia or
incompletely healed osteomalacia, and that vitamin D has been provid-
ed to assist with healing. Accordingly, this baseline skeletal
hypomineralization may have impaired the BMD response to
teriparatide treatment. An alternative explanation is that this effect
could be related to the role of vitamin D as an inducer of osteoclast for-
mation via its promotion of receptor activator of nuclear factor-kB li-
gand (RANKL) expression. This effect of vitamin D supplementation
has been hypothesized to increase bone resorption and decrease the ef-
ﬁcacy of bisphosphonates in patients with metastatic bone tumors
(Altundag et al., 2004). A recent study showed that this effect can be re-
versed in vivo by demonstrating that daily administration of active vita-
min D compounds suppresses bone resorption in animal models
(Takahashi et al., 2014). Nevertheless, the in vitro negative effect of vi-
tamin D could still explain its association with a decreased skeletal ana-
bolic responsewhen combinedwith teriparatide, particularly given that
teriparatide itself increases osteoclast activity.
To our knowledge, our study is the ﬁrst to attempt to identify predic-
tors of treatment failure in subjects treated with teriparatide. A recent
study by Diez-Perez et al. (2014) assessed predictors for anti-
osteoporosis medications in general. While their analysis included pro-
spectively collected data and therefore allowed assessment of somevar-
iables for which we were unable to test, our study design allowed us to
collect data on vitamin D supplementation and BMD, factors which to
our knowledge have not been previously studied. Of note, our ﬁndings
with regards to bisphosphonate treatment are supported by two studiesMD response
n = 322)
OR
(95% CI)
P value
66.0 (12.8) 1.00 (0.98–1.01) 0.890
4/258 (19.8/80.2) 0.89 (0.53–1.48) 0.649
72 (22.4) 1.06 (0.67–1.69) 0.795
48 (14.9) 0.94 (0.54–1.61) 0.816
102 (31.7) 1.50 (1.01–2.24) 0.045a
125 (38.8) 1.19 (0.77–1.84) 0.434
66 (20.5) 1.08 (0.68–1.73) 0.744
64 (19.9) 0.84 (0.51–1.39) 0.509
150 (46.6) 1.50 (1.01–2.22) 0.043a
n pump inhibitors.
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(Ettinger et al., 2004; Koski et al., 2013), both of which demonstrated
that prior bisphosphonate treatment was associated with reduced
BMD response. In contrast, however, a retrospective study from the
UK reported that no differences were detected in BMD change from
baseline when patients were stratiﬁed based on whether or not they
had received prior bisphosphonate therapy (Middleton et al., 2007), re-
sults similar to those reported in another European study (Boonen et al.,
2008). In comparison, a study that evaluated teriparatide treatment fol-
lowing treatment with either alendronate or risedronate found that in-
creases in BMD above 3% at the lumbar spine did still occur following
bisphosphonate pretreatment but were greater in patients who had
previously been treated with risedronate, suggesting that the skeletal
anabolic response to teriparatide differs based on prior bisphosphonate
therapy (Miller et al., 2008).
Our study has several limitations inherent to the design. For exam-
ple, it is prone to potential bias due to missing data because some of
the variables studiedwere, in limited cases, not adequately documented
in themedical record.We acknowledge this may have affected our ﬁnal
analyses, although given the relatively few instances of missing data,
this issue likely had limited impact on our ﬁndings. It should also be
noted that such studies are inherently susceptible to exposure ascer-
tainment bias. To prevent this, investigators were blinded to the out-
come status of the patient, and we ensured that exposure
ascertainment was done similarly for all subjects. Another threat to
our results is under reporting of fracture occurrence, particularly since
vertebral fractures are frequently subclinical and thus not always diag-
nosed (Gehlbach et al., 2000; Delmas et al., 2005; Hajcsar et al., 2000;
Kim et al., 2004).
Despite these limitations, our study has signiﬁcant strengths, includ-
ing our ability to speciﬁcally study the predictors of teriparatide failure
using data identiﬁed directly from real clinical practice. Importantly,
such data are direly needed yet currently very scarce; thus, our study
has considerablemerit. Indeed, our study included the largest longitudi-
nally followed (spanning the course of an entire decade) cohort of pa-
tients treated with teriparatide to date, and also included both men
and women with low bone mass without restriction to speciﬁc age
group, thereby providing broader applicability to its inferences.
Collectively, the baseline variables tested in our study were unable
to fully predict teriparatide treatment failure in low bonemass patients.
Given the limitations associated with our study design, prospective ob-
servational studies that allow for better control over study variables will
likely providemore conclusive results, as such designs allow for the col-
lection of additional factors that we were unable to assess (e.g., falls,
physical activity and function, and dietary intakes). It is alsoworthmen-
tioning thatwith only 35 fracture patients, our studymay have been un-
derpowered to detect signiﬁcant predictors of this endpoint. Therefore,
future larger studies to address this particular endpoint are needed.
In terms of the practical implications of our ﬁndings, the data pre-
sented here are useful for informing patients and physicians contem-
plating treatment decisions. Although teriparatide is currently the
only available skeletal anabolic agent, optimal shared decision making
requires conveying the uncertainty to patients. Informing patients
about the possibility of - and potential predictors for - treatment failure,
and providing them with quantitative estimates about an expensive
treatment that requires daily injection is important, and will help pa-
tients to make decisions consistent with their values and preferences.5. Conclusion
Prior treatment with bisphosphonate and vitamin D are indepen-
dent predictors of teriparatide therapy failure. Further prospective stud-
ies are needed to establish whether these ﬁndings reﬂect increased
severity or longer duration of disease, as well as additional factors that
predict treatment failure response to teriparatide. Such knowledgeshould help patients and clinicians engage in shared decision making
when therapy choices are made.
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